Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus MONISTAT 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus MONISTAT 5.
MICONAZOLE 7 vs MONISTAT 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
Miconazole nitrate 100 mg vaginal suppository inserted once daily at bedtime for 3 days; or 200 mg vaginal suppository once daily at bedtime for 3 days; or 1200 mg vaginal suppository as a single dose.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Terminal half-life approximately 24 hours; supports once-daily dosing.
Primarily fecal (~50%) and renal (~<1% unchanged)
Primarily fecal (90%) as unchanged drug; renal excretion minimal (<1%).
Category A/B
Category C
Antifungal
Antifungal